Y-Intercept (HK)’s Castle Biosciences CSTL Stock Holding History

Y-Intercept (HK)’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-31,916	Closed	-$761K	–	1665
2026 Q2	$761K	Buy	31,916 +8,415	+36%	+$187K	0.02%	1158
2026 Q1	$577K	Buy	23,501 +10,255	+77%	+$336K	0.01%	1227
2025 Q4	$515K	Buy	+13,246	New	+$427K	0.01%	1229
2025 Q3	–	Sell	-78,938	Closed	-$1.61M	–	1649
2025 Q2	$1.61M	Buy	+78,938	New	+$1.46M	0.04%	701
2025 Q1	–	Sell	-21,839	Closed	-$582K	–	1270
2024 Q4	$582K	Sell	21,839 -2,367	-10%	-$72.1K	0.04%	661
2024 Q3	$690K	Buy	24,206 +845	+4%	+$21.5K	0.04%	618
2024 Q2	$509K	Sell	23,361 -1,242	-5%	-$27.7K	0.03%	798
2024 Q1	$545K	Buy	24,603 +14,010	+132%	+$305K	0.04%	669
2023 Q4	$229K	Buy	+10,593	New	+$186K	0.02%	941

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return

Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Y-Intercept (HK)'s CSTL Position: Q3 2026 in Review

Y-Intercept (HK) sold out of Castle Biosciences (CSTL) in Q3 2026, closing a stake of 31,916 shares — an estimated $761K sold.

Y-Intercept (HK) first reported a position in CSTL in Q4 2023 and held it in 9 quarters. The position peaked at $1.61M in Q2 2025. 24 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Y-Intercept (HK) reported no remaining Castle Biosciences position as of Q3 2026 after selling out during the quarter.
Y-Intercept (HK) sold 31,916 Castle Biosciences shares in Q3 2026, an estimated $761K.
Y-Intercept (HK) first reported a position in Castle Biosciences in Q4 2023 and held it in 9 quarters.
Y-Intercept (HK)'s Castle Biosciences position peaked at $1.61M in Q2 2025.
24 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.